17V Stock Overview
Develops and commercializes healthcare products in the United Kingdom, the Netherlands, China, Germany, Italy, Switzerland, rest of Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Venture Life Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.45 |
| 52 Week High | UK£0.57 |
| 52 Week Low | UK£0.37 |
| Beta | 0.32 |
| 11 Month Change | -7.44% |
| 3 Month Change | -14.67% |
| 1 Year Change | 19.15% |
| 33 Year Change | -0.44% |
| 5 Year Change | n/a |
| Change since IPO | -50.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 17V | DE Personal Products | DE Market | |
|---|---|---|---|
| 7D | -3.0% | 3.9% | 1.1% |
| 1Y | 19.1% | -4.8% | 7.2% |
Return vs Industry: 17V exceeded the German Personal Products industry which returned -5.6% over the past year.
Return vs Market: 17V exceeded the German Market which returned 8.6% over the past year.
Price Volatility
| 17V volatility | |
|---|---|
| 17V Average Weekly Movement | 4.1% |
| Personal Products Industry Average Movement | 3.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 17V has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 17V's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 165 | Jerry Randall | www.venture-life.com |
Venture Life Group plc develops and commercializes healthcare products in the United Kingdom, the Netherlands, China, Germany, Italy, Switzerland, rest of Europe, and internationally. The company offers oral healthcare products, including mouthwash, toothpaste, breath freshening capsules, and dental accessories under UltraDEX and Dentyl Dual Action brands; and proctology products, such as Procto-eze Plus range for treating the discomfort caused by haemorrhoids. It also provides dermatology products comprising Myco Clear, a fungal nail cleanser and solution brand; Rosa calma for normalizing and controlling the signs and symptoms related to rosacea; Bioscalin for the cosmetic treatment and prevention of hair loss, hair thinning, and baldness; and skincare solutions under the brand Lubatti.
Venture Life Group plc Fundamentals Summary
| 17V fundamental statistics | |
|---|---|
| Market cap | €57.94m |
| Earnings (TTM) | €890.43k |
| Revenue (TTM) | €61.69m |
65.1x
P/E Ratio0.9x
P/S RatioIs 17V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 17V income statement (TTM) | |
|---|---|
| Revenue | UK£51.41m |
| Cost of Revenue | UK£31.04m |
| Gross Profit | UK£20.37m |
| Other Expenses | UK£19.63m |
| Earnings | UK£742.00k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0058 |
| Gross Margin | 39.62% |
| Net Profit Margin | 1.44% |
| Debt/Equity Ratio | 21.7% |
How did 17V perform over the long term?
See historical performance and comparison